Advertisement
BMY vs GSK
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. GSK (GSK) Stock Comparison
Key Takeaways
- Bristol-Myers Squibb (BMY) and GSK plc (GSK) are both major pharmaceutical companies with significant exposure to oncology, immunology, and specialty medicines.
- Year-to-date, BMY has delivered approximately 11% total return while GSK has posted around 9%, though GSK shows stronger one-year performance near 40% compared to BMY's 27%.
- Both stocks trade in a sector facing patent expirations and pipeline competition, with upcoming quarterly results expected to provide clarity on growth trajectories.
- BMY emphasizes its growth portfolio to offset legacy product declines, while GSK highlights diversification across vaccines, HIV, and respiratory treatments.
- Market sentiment for both remains influenced by broader healthcare trends, regulatory developments, and relative valuation metrics such as price-to-earnings ratios.
- AI-driven analysis of trend consistency and relative momentum currently tilts toward GSK for short-term positioning, though both exhibit defensive characteristics typical of large-cap pharma.
Introduction
Pharmaceutical stocks Bristol-Myers Squibb (BMY) and GSK plc (GSK) represent established players in the global healthcare sector, each navigating patent cliffs, pipeline advancements, and evolving market dynamics. Investors and traders often compare these names when seeking exposure to large-cap biopharma with dividend yields and defensive qualities amid economic uncertainty. This analysis examines recent performance patterns, business fundamentals, and relative positioning to assist those evaluating portfolio allocation or short-term trading opportunities in the sector.
BMY Overview and Recent Performance
Bristol-Myers Squibb (BMY) is a global biopharmaceutical company focused on oncology, hematology, immunology, and cardiovascular treatments. In recent market activity, the stock has shown resilience with year-to-date gains near 11%, outperforming the broader S&P 500 in that timeframe while trading within a 52-week range of approximately $42.50 to $62.90. Sentiment has been shaped by management guidance indicating modest sales contraction for the full year, tempered by expectations for new product launches and pipeline progress. Upcoming second-quarter results are anticipated to highlight execution on the growth portfolio amid ongoing competition in key therapeutic areas.
GSK Overview and Recent Performance
GSK plc (GSK) operates as a science-led global healthcare company with strengths in vaccines, specialty medicines including HIV and respiratory therapies, and oncology. Recent market activity reflects steady gains, with year-to-date returns around 9% and notably stronger one-year performance approaching 40%. Investor focus centers on portfolio diversification and upcoming second-quarter results scheduled for late July, which are expected to provide updates on growth initiatives. The stock has benefited from alliances in respiratory treatments and broader sector tailwinds, trading in a range that underscores its defensive appeal relative to more volatile growth-oriented peers.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI-powered trading bots drawn from hundreds available across the platform. These bots cover thousands of tickers and employ varied strategies, timeframes, and performance profiles, yet only those demonstrating the strongest alignment with prevailing market conditions earn placement in the trending section. Users can review statistics such as win rates, profit factors, and drawdowns that typically range across wide spectra depending on the bot’s design and historical results. The section serves as a dynamic resource for traders seeking data-driven signals without replacing individual due diligence.
Head-to-Head Comparison
Bristol-Myers Squibb (BMY) and GSK plc (GSK) differ in portfolio emphasis: BMY concentrates more heavily on oncology and cell therapies, while GSK maintains broader diversification including vaccines and established HIV franchises. Recent momentum favors BMY on a year-to-date basis, yet GSK exhibits superior longer-term returns and potentially lower volatility in certain periods. Both face similar risk factors such as regulatory scrutiny and generic competition, though sector exposure remains comparable within large-cap pharmaceuticals. Market sentiment reflects defensive characteristics for each, with valuation metrics like price-to-earnings ratios often cited in relative assessments. Trade-offs include BMY’s higher near-term growth expectations versus GSK’s stronger historical price appreciation and dividend profile.
Tickeron AI Verdict
Based on observable factors including trend consistency over recent weeks and relative positioning within the healthcare sector, Tickeron’s AI models currently assign a probabilistic edge to GSK plc (GSK). This assessment incorporates stronger one-year momentum and portfolio stability indicators, though outcomes remain subject to earnings volatility and broader market conditions. Investors should monitor upcoming quarterly reports for confirmation of these patterns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a StrongBuy and GSK is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 2 FA rating(s) are green whileGSK’s FA Score has 1 green FA rating(s).
- BMY’s FA Score: 2 green, 3 red.
- GSK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 6 TA indicator(s) are bullish while GSK’s TA Score has 5 bullish TA indicator(s).
- BMY’s TA Score: 6 bullish, 4 bearish.
- GSK’s TA Score: 5 bullish, 2 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а -0.95% price change this week, while GSK (@Pharmaceuticals: Major) price change was -1.64% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.40%. For the same industry, the average monthly price growth was +12.67%, and the average quarterly price growth was +6.87%.
Reported Earning Dates
BMY is expected to report earnings on Jul 30, 2026.
GSK is expected to report earnings on Jul 28, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-2.40% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| BMY | GSK | BMY / GSK | |
| Capitalization | 118B | 104B | 113% |
| EBITDA | 15B | 10.1B | 149% |
| Gain YTD | 10.355 | 9.483 | 109% |
| P/E Ratio | 16.13 | 14.07 | 115% |
| Revenue | 48.5B | 32.8B | 148% |
| Total Cash | N/A | 3.44B | - |
| Total Debt | 46.4B | 19.1B | 243% |
BMY | GSK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 20 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 81 Overvalued | |
PROFIT vs RISK RATING 1..100 | 93 | 39 | |
SMR RATING 1..100 | 25 | 27 | |
PRICE GROWTH RATING 1..100 | 49 | 50 | |
P/E GROWTH RATING 1..100 | 63 | 78 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMY's Valuation (3) in the Pharmaceuticals Major industry is significantly better than the same rating for GSK (81). This means that BMY’s stock grew significantly faster than GSK’s over the last 12 months.
GSK's Profit vs Risk Rating (39) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (93). This means that GSK’s stock grew somewhat faster than BMY’s over the last 12 months.
BMY's SMR Rating (25) in the Pharmaceuticals Major industry is in the same range as GSK (27). This means that BMY’s stock grew similarly to GSK’s over the last 12 months.
BMY's Price Growth Rating (49) in the Pharmaceuticals Major industry is in the same range as GSK (50). This means that BMY’s stock grew similarly to GSK’s over the last 12 months.
BMY's P/E Growth Rating (63) in the Pharmaceuticals Major industry is in the same range as GSK (78). This means that BMY’s stock grew similarly to GSK’s over the last 12 months.
| BMY | GSK | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 30% | N/A |
| Stochastic ODDS (%) | 1 day ago 53% | 1 day ago 46% |
| Momentum ODDS (%) | 1 day ago 47% | 1 day ago 67% |
| MACD ODDS (%) | 1 day ago 61% | N/A |
| TrendWeek ODDS (%) | 1 day ago 56% | 1 day ago 53% |
| TrendMonth ODDS (%) | 1 day ago 56% | 1 day ago 57% |
| Advances ODDS (%) | 12 days ago 53% | 12 days ago 62% |
| Declines ODDS (%) | 10 days ago 55% | 2 days ago 54% |
| BollingerBands ODDS (%) | 1 day ago 60% | N/A |
| Aroon ODDS (%) | 1 day ago 59% | 1 day ago 51% |
Advertisement